Novo Nordisk's Journalist Profile | prnewswire.com

The Media Database That Really Understands Journalists

Explore Our Database And See What Journalists Create So You Can Better Connect 🫶

Media Database P prnewswire.com Novo Nordisk

Novo Nordisk

followers

Lasting Health Starts Now. Stay tuned for news and the latest in innovation 🩵 Community guide

Publications:

prnewswire.com

Topics

biotech, cassianstocks, companies, diabetes, health, healthcare, novo nordisk, pharma, pharma companies, pharmaceutical companies

Recent articles

Singlife Launches Singapore's First Insurer-led Chronic Care Programme for Weight Management with Novo Singapore and HMI Medical

Oct 15, 2026

Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

Sep 29, 2026

Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

Sep 29, 2026

Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

Sep 29, 2026

prnewswire.co.uk

Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis

Sep 23, 2026

Novo Nordisk Saudi Arabia launches "Live Lighter" campaign to mark Saudi National Day

Sep 22, 2026

saudionlinecom.com

Novo Nordisk Saudi Arabia launches “Live Lighter” campaign to mark Saudi National Day

Sep 22, 2026

Novo's denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with hemophilia A as published in the Journal of Thrombosis and Haemostasis

Sep 17, 2026

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Aug 24, 2026

Novo Nordisk obtiene en México la primera aprobación en América Latina para semaglutida oral 25 mg (Wegovy® tabletas) marcando una nueva era en el manejo oral del peso

Aug 18, 2026

Find out everything there is to know

Publication resume, most loved topics, and more. Find out everything there is to know about a journalist, in our 500k+ database.

Start a free trial of BuzzSumo.

START YOUR FREE TRIAL

Already registered? Log in to your account